ArticleFrontiers in pharmacology2026
Safety profile of upadacitinib in inflammatory Bowel disease: a dual-source pharmacovigilance study integrating FAERS signal detection and real-world clinical cohort analysis.
Wei Tan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.